Browse by category

In a major new study, researchers from Intermountain Health in Salt Lake City have found that GLP-1 receptor agonists used by patients who have high triglycerides do not increase their risk of pancreatitis or adverse cardiac events, and for those who have never had pancreatitis, being on a GLP1RA medication led to a four times lower risk of developing the condition. "Pancreatitis is incredibly painful and can be deadly. Once you have a patient with acute pancreatitis, you wan

Scientists at Washington University School of Medicine (WashU Medicine)   in St Louis and the Veterans Affairs (VA) St Louis Health Care...

An analysis of real-world evidence from the FDA Adverse Event Reporting System (FAERS) database of tirzepatide, presented at this year's...